Durvalumab - CISMeF

Preferred Label : Durvalumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer;

NCIt definition : A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.;

UNII : 28X28X9OKV;

CAS number : 1428935-60-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1428935-60-7 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Imfinzi;

Molecule name : MEDI-4736;

Codes from synonyms : 173;

Details

Origin ID

C103194;

UMLS CUI

C4055109;

Automatic exact mappings (from CISMeF team)
- Durvalumab [ICD-11 Extension code]
Currated CISMeF NLP mapping
- Durvalumab (substance) [SNOMED CT concept]
- durvalumab [MeSH Supplementary Concept]
- durvalumab [MeSH concept]
See also inter- (CISMeF)
- Imfinzi [MeSH concept]
- Product containing durvalumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Durvalumab (substance) [SNOMED CT concept]
- Product containing durvalumab (medicinal product) [SNOMED CT concept]
- durvalumab [MeSH Supplementary Concept]
- durvalumab [ATC Code]
Validated automatic mappings to BTNT
- durvalumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Programmed Cell Death 1 Ligand 1 [NCIt concept]
is_component_of_chemotherapy_regimen
- Carboplatin/Durvalumab/Etoposide Regimen [NCIt concept]
- Carboplatin/Durvalumab/Gemcitabine/Tremelimumab Regimen [NCIt concept]
- Carboplatin/Durvalumab/Nab-paclitaxel/Tremelimumab Regimen [NCIt concept]
- Carboplatin/Durvalumab/Pemetrexed/Tremelimumab Regimen [NCIt concept]
- Cisplatin/Durvalumab/Etoposide Regimen [NCIt concept]
- Cisplatin/Durvalumab/Gemcitabine Regimen [NCIt concept]
- Cisplatin/Durvalumab/Gemcitabine/Tremelimumab Regimen [NCIt concept]
- Cisplatin/Durvalumab/Pemetrexed/Tremelimumab Regimen [NCIt concept]
- Durvalumab Regimen [NCIt concept]
- Durvalumab/Tremelimumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients